What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: Biogen
96%DGNews: Major Step Toward European Approval of Interferon Beta-1a
94%DGNews: FDA Approves Labeling Change for Biogen's Avonex (Interferon Beta-1a) to Indicate Lower Occurrence of Neutralizing Antibodies
94%DGNews: Biogen's Avonex (Interferon beta-1a) Approved in Europe for Treatment of Patients at High Risk for Developing Multiple Sclerosis
92%DGNews: FDA Advisory Committee Recommends Approval of Biogen's Amevive (Alefacept)
92%DGNews: Avonex Cleared by FDA for Relapsing Forms of Multiple Sclerosis
92%DGNews: Antegren (Natalizumab) Promising Treatment For Multiple Sclerosis, Crohn's Disease
92%DGNews: AAN: Avonex (interferon beta-1a) helps delay development of multiple sclerosis
91%DGNews: Tysabri Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in Multiple Sclerosis
91%DGNews: New Safety Information for Amevive (alefacept)
91%DGNews: FDA Approves Prefilled Syringe for Multiple Sclerosis Therapy, Avonex (Interferon Beta-1a)
91%DGNews: Neurology Study Finds Approved Dose of Avonex (Interferon Beta-1a) Equally Effective as Higher Dose in Treating Relapsing Multiple Sclerosis
90%DGNews: FDA Approves Resumed Marketing of Tysabri (Natalizumab) Under Special Distribution Program
90%DGNews: Health Canada Approves Amevive (Alefacept), Treatment for Psoriasis
90%DGNews: Amevive (Alefacept), Treatment for Psoriasis, Approved In Australia
90%DGNews: FDA Approves Avonex (Interferon beta-1a) Approved for Patients with Early Multiple Sclerosis
90%DGNews: ECTRIMS: Antegren (Natalizumab) Shows Promise In Multiple Sclerosis, Crohn's Disease
90%DGNews: DDW: Antegren (Natalizumab) Looks Promising For Crohn's Disease
90%DGNews: Weekly Avonex (Interferon Beta-1a) Effective In Reducing Disability Progression In Multiple Sclerosis
89%DGNews: Tysabri (Natalizumab) Receives Approval in European Union for Treatment of Relapsing Remitting Forms of Multiple Sclerosis
89%DGNews: Clinical Data on Volociximab (M200) Presented at the American Society of Clinical Oncology Annual Meeting
89%DGNews: Amevive (Alefacept), Treatment for Psoriasis, Approved in Israel, Receives 'Positive Opinion' From Swiss Regulatory Authority
89%DGNews: FDA Approves Amevive (Alefacept) For Treatment of Psoriasis
89%DGNews: ECTRIMS: Avonex (Interferon beta-1a) Shows Effect on Primary Progressive Multiple Sclerosis
88%DGNews: Amevive Provides Therapeutic Effect For Psoriasis
87%DGNews: Genentech and Biogen Idec Announce Positive Results From a Phase 2 Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
87%DGNews: Antegren 1-Year Data Show Compelling Results in Meeting Primary Endpoint in Multiple Sclerosis
87%DGNews: ECTRIMS: New Study Shows Long-Term Effect Of Avonex (Interferon beta-1a) On Multiple Sclerosis
87%DGNews: Canada Approves Avonex (Interferon Beta-1a), Delays Onset of Multiple Sclerosis
87%DGNews: Avonex (Interferon Beta-1a) Slows Progression In Secondary Multiple Sclerosis
86%DGNews: FDA Approves TYSABRI® (natalizumab) for the Treatment of Moderate-to-Severe Crohn's Disease
86%DGNews: CHMP Issues Positive Opinion for Tysabri (Natalizumab) as a Treatment for Relapsing-Remitting Multiple Sclerosis
86%DGNews: European Commission Approves Zevalin (Ibritumomab tiuxetan) Radioimmunotherapy
86%DGNews: AAD: Positive Results In Retreatment With Amevive (Alefacept) For Chronic Plaque Psoriasis
86%DGNews: Avonex (Interferon Beta-1a) Slows Progression In Secondary Multiple Sclerosis
85%DGNews: FDA Grants Priority Review for Rituxan (Rituximab) Supplemental Biologics License Application for Front-Line Treatment of Intermediate-Grade or Aggressive Non-Hodgkin's Lymphoma
85%DGNews: Efficacy and Safety of Interferon Beta-1a (Avonex) Appears Unaffected by Gender of Patient: Presented at ECTRIMS
85%DGNews: Recent Study Shows Treatment-Free Periods with New Biologic, Alefacept for Psoriasis
85%DGNews: AAD: Second Course Of Alefacept Provides Continued Response Against Chronic Plaque Psoriasis
85%DGNews: AAN: Many Multiple Sclerosis Patients Are Not Getting Adequate Treatment
85%DGNews: ENS: Higher Dose Avonex (Interferon-ß-1a) Not More Effective Than Currently Approved Dose In Multiple Sclerosis
85%DGNews: AIDS Research to Focus on Management Therapy
84%DGNews: Intramuscular Interferon Therapy Shows Greater Compliance Than Other Disease-Modifying Therapies: Presented at ENS
84%DGNews: Prednisone, Acetaminophen Equally Effective in Controlling Flulike Symptoms Associated With Interferon-Beta Therapy: Presented at ENS
84%DGNews: FDA Approves Two New Indications for Rituxan(R) (Rituximab) in Patients With Non-Hodgkin's Lymphoma
84%DGNews: AAD: Alefacept (Amevive) Biologic Therapy As Effective In Severe Psoriasis As In Milder Cases
83%DGNews: Natalizumab Therapy Significantly Improves Quality of Life in Patients With Highly Active Relapsing MS: Presented at ENS
83%DGNews: FDA Approves Rituxan (Rituximab), the First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
83%DGNews: AAN MEETING: Drug Therapy Slows Rate Of Brain Shrinkage In MS
83%DGNews: Early Drug Treatment May Preserve Brain Tissue In MS Patients
82%DGNews: FDA Approves Rituxan (Rituximab) Plus CHOP or Other Anthracycline-Based Chemotherapy Regimens for First-Line Treatment of Diffuse Large B-cell Non-Hodgkin's Lymphoma
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.